Application of antagonist of integrin alpha M beta2 to preparation of medicine for treating blood platelet quantity related diseases

Abstract

The invention discloses application of an antagonist of integrin alpha M beta2 to preparation of a medicine for treating blood platelet quantity related diseases. The blood platelet quantity related diseases include idiopathic or secondary thrombocytopenia and idiopathic or secondary thrombocytosis. The antagonist of the integrin alpha M beta2 can be an anti-integrin alpha M beta2 antibody, amino acid sequence polypeptide and oligopeptide of the integrin alpha M beta2, derivatives and analogues of the amino acid sequence polypeptide and oligopeptide of the integrin alpha M beta2, and a small-molecular compound antagonist of the integrin alpha M beta2. The invention discloses the application of the antagonist of the integrin alpha M beta2 to the preparation of the medicine for treating the blood platelet quantity related diseases for the first time.

Description

technical field [0001] The invention relates to the field of medicine, in particular to integrin alpha Μ beta 2 The application of the antagonist in the preparation of medicines for the treatment of diseases related to the number of platelets. Background technique [0002] Clinically, abnormal platelet counts caused by various factors can cause related diseases, such as primary or secondary thrombocytosis, primary or secondary thrombocytopenia, including immune thrombocytopenia, etc. Thrombocytosis is a myeloproliferative disorder characterized by abnormal hyperplasia of unknown cause accompanied by persistent increase of platelets. Thrombosis, splenomegaly, and platelet persistence increased significantly, and the etiology was unknown. The bleeding mechanism of this disease may be related to platelet dysfunction or enhanced fibrinolysis. According to the epidemiological survey of essential thrombocythemia in 5 European and American countries, the incidence rate is 0.59 / ...

AI Technical Summary

Problems solved by technology

[0006] The current therapeutic drugs are mainly hematopoietic factors thrombopoietin, interleukin-11, glucocorticoids for immune intervention, monoclonal antibodies, etc. However, each of the above-mentioned therapeutic drugs has its own limitations. RhTPO has potential side effects such as thrombosis, myelofibrosis, and venous blockage; intravenous immunoglobulin (IVIG) is suitable for refractory or urgently treated ITP patients, with mild side effects and unlimited use, but due to its action time Short, expensive, and limited clinical application (Beardsley DS, Ertem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci. 1998; 19:237-244)

Images